Skip to main content
Show — Main navigation
Hide — Main navigation
Hair & Scalp
Expert Insights in AD
Cutaneous & COVID
AAD VMX 2020
Insights from AAD VMX 2020
Centers of Excellence
Thu, 06/11/2020 - 16:20
Open-label Study Finds DaxibotulinumtoxinA for Injection Safe for Glabellar Lines
Researchers found that daxibotulinumtoxinA for injection (DAXI), a novel botulinum toxin in development, is safe with high response rat
Prof Reich on the Results of BE-VIVID and BE-READY, Two Phase 3 Clinical Trials on Bimekizumab, an IL-17A/IL-17F Inhibitor
Kristian Reich, MD, PhD, discusses the results of two phase 3 clinical trials, BE-READY and BE-VIVID, that tested the efficacy and safety of bimekizumab, a novel IL-17A/IL-17F inhibitor.
Dr Katz on Neuromodulators and Cosmetic Dermatology
Bruce M. Katz, MD, discusses the results of two phase 3 clinical trials on daxibotulinumtoxinA for injection, the development of a onabotulinumtoxinA biosimilar, and the current state and future of cosmetic dermatology practice.
HS Diagnosis Delays Affected by Insurance
A recent poster abstract investigated the impact of insurance type, such as private or Medicaid, on delay in diagnosis among patients with hidradenitis suppurativa.
Hair May Impact Ability to Detect Scalp Melanomas
Findings from a recent study found hair coverage and visibility of the scalp may be factors in the detection of melanomas on the scalp.
Do Topical Steroids Increase Diabetes Risk?
Findings from a recent poster abstract highlight the potential association between cumulative steroid use and diabetes risk.
Ustekinumab Investigated as Potential HS Therapy
In a small study, researchers assessed the safety and efficacy of ustekinumab intravenous induction among patients with severe hidradenitis suppurativa.
ABCD Criteria Still Effective, Study Shows
While the “ABCD” acronym (Asymmetry, Border, Color, Diameter) was developed more than 35 years ago, modern clinicians may wonder if its
Survey Finds Patients Most Satisfied With IL-17 Inhibitors, 4-Week Dosing
A recent study found that patients had the highest overall treatment satisfaction with anti-IL-17 class therapies. The poster, presente
Abrocitinib Rapidly Improves Pruritus in Patients with Atopic Dermatitis
Findings from a recent poster abstract presented at the American Academy of Dermatology Virtual Meeting Experience 2020 showed promising results for abrocitinib, an oral Janus kinase inhibitor.
Stay in the know.
The Dermatologist Newsletter
Back to Top